Kelly D. Sullivan

TL;DR: This review focuses on recent advances in the understanding of mechanisms of p53-dependent transcriptional control as they relate to five key areas: the functionally distinct N-terminal transactivation domains, the diverse regulatory roles of its C-Terminal domain, evidence that p53 is solely a direct transcriptional activator, not a direct repressor, and the ability of the p53 to recognize many of its enhancers across diverse chromatin environments.

TL;DR: GRO-seq uncovered a plethora of gene-specific regulatory features affecting key survival and apoptotic genes within the p53 network, and strikingly, direct p53 targets harbor pre-activated enhancers highly transcribed in p53 null cells.

TL;DR: It is proposed thatInterferon activation, likely via increased gene dosage of the four interferon receptors encoded on chromosome 21, contributes to many of the clinical impacts of trisomy 21, and thatinterferon antagonists could have therapeutic benefits.

TL;DR: A link between two processes mediated via a single transcription factor binding site in the genome can be leveraged to improve anti-cancer therapies.

TL;DR: Results from proteomics approaches are consistent with the hypothesis that increased interferon signaling caused by T21 leads to chronic immune dysregulation, and justify investigations to define the therapeutic value of immune-modulatory strategies in DS.